Leflunomide
Leflunomide is a disease-modifying antirheumatic drug (DMARD) used primarily to treat active rheumatoid arthritis and psoriatic arthritis in eligible patients. It works by inhibiting the enzyme dihydroorotate dehydrogenase, reducing pyrimidine synthesis and limiting the proliferation of activated lymphocytes involved in joint inflammation and tissue damage. It is commonly available as oral tablets, with treatment often initiated using a loading or maintenance-dose regimen according to the patient’s condition and prescribing guidance. Common side effects include diarrhoea, nausea, hair loss, rash, and elevated liver enzymes. Important precautions include regular monitoring of liver function and blood counts because leflunomide may cause liver injury, bone marrow suppression, and increased susceptibility to infections. It can cause serious fetal harm and is contraindicated during pregnancy; effective contraception and a medically supervised drug-elimination procedure may be required when discontinuing treatment in patients planning pregnancy.
Leflunomide was historically used as a respiratory medicine for the symptomatic management of certain respiratory conditions. Its former uses included:
is okay
The import of medicines into India is regulated by the Central Drugs Standard Control Organisation (CDSCO) under the Drugs and Cosmetics Act, 1940, and the Drugs and Cosmetics Rules, 1945. The regulatory requirements depend on whether the product is an active pharmaceutical ingredient (API), a finished formulation, or an unapproved medicine intended for an individual patient's treatment.
Primeera Healthcare Private Limited can provide import coordination and pharmaceutical documentation assistance for Leflunomide, subject to confirmation of its current regulatory status and eligibility for import into India.
The export of Leflunomide from India is subject to applicable requirements under the Drugs and Cosmetics Act, 1940, the Drugs and Cosmetics Rules, 1945, and relevant export, customs, and destination-country regulations. Documentation requirements depend on whether the product is an active pharmaceutical ingredient (API), a finished pharmaceutical formulation, or a medicine intended for a specific market. Export eligibility and destination-country requirements must be verified before shipment.
Primeera Healthcare Private Limited can provide pharmaceutical export documentation assistance, regulatory coordination, and shipping support for Leflunomide, subject to confirmation of its export eligibility under applicable Indian regulations and the import requirements of the destination country.
If you have any questions or need any help, contact our Support Team. We will get in touch with you within 24 hours from Monday to Friday between 9:00 and 10:00 CET.
All Trademarks and Brands that appear on the website belong to their respective owners. Primeera Healthcare does not lay any claim on them; we only provide information.
